Literature DB >> 12944978

Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.

S Knapp1, L J Yee, A J Frodsham, B J W Hennig, S Hellier, L Zhang, M Wright, M Chiaramonte, M Graves, H C Thomas, A V S Hill, M R Thursz.   

Abstract

Interferon stimulates the expression of a number of genes encoding enzymes with antiviral activities, including myxovirus resistance-1 (MxA), 2-5-oligoadenylate synthetase 1 (OAS-1) and double-stranded RNA-dependent protein kinase (PKR). We examined whether polymorphisms in these genes influenced the outcome of hepatitis C virus (HCV) infection. We observed a lower frequency of the GG genotype at position -88 in the MxA gene promoter in self-limiting HCV infection (OR=0.56; 95% CI: 0.35-0.8; P=0.010) and in nonresponders to therapy (OR=0.49; 95% CI: 0.25-0.95; P=0.020). This genotype predominantly influenced the outcome of treatment in patients with viral genotype 1 (OR=0.22 95% CI: 0.07-0.67; P=0.002). A polymorphism in the 3'-untranslated region of the OAS-1 gene was associated with outcome of infection (GG genotype less frequent in self-limiting infection: OR=0.43; 95% CI: 0.21-0.86; P=0.010). A polymorphism at position -168 in the promoter region of the PKR gene was associated with self-limiting infection (CT genotype: OR=2.75; 95% CI: 1.45-5.24; P=0.002). Further associations were found with a CGG trinucleotide repeat in the 5'UTR region of the PKR gene. Polymorphisms in the interferon-induced genes, MxA, OAS-1 and PKR appear thus associated with HCV outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944978     DOI: 10.1038/sj.gene.6363984

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  74 in total

Review 1.  Genetics of liver disease: immunogenetics and disease pathogenesis.

Authors:  P T Donaldson
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

2.  Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Authors:  Folkert Steinhagen; Corinna Meyer; Debra Tross; Mayda Gursel; Takahiro Maeda; Sven Klaschik; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2012-07-02       Impact factor: 4.962

Review 3.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

4.  Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus.

Authors:  Timothy L Mosbruger; Priya Duggal; James J Goedert; Gregory D Kirk; W Keith Hoots; Leslie H Tobler; Michael Busch; Marion G Peters; Hugo R Rosen; David L Thomas; Chloe L Thio
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

Review 5.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

6.  ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication.

Authors:  Harini Sooryanarain; Adam J Rogers; Dianjun Cao; Mary Etna R Haac; Yogesh A Karpe; Xiang-Jin Meng
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

7.  Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection.

Authors:  Kyung-Ah Kim; Wenyu Lin; Andrew W Tai; Run-Xuan Shao; Ethan Weinberg; Carolina B De Sa Borges; Atul K Bhan; Hui Zheng; Yoshitaka Kamegaya; Raymond T Chung
Journal:  J Hepatol       Date:  2009-02-14       Impact factor: 25.083

8.  Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients.

Authors:  S Mascheretti; H Hinrichsen; S Ross; P Buggisch; J Hampe; U R Foelsch; S Schreiber
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

9.  Prevalence of the SNP rs10774671 of the OAS1 gene in Mexico as a possible predisposing factor for RNA virus disease.

Authors:  María Teresa Sánchez-González; Oscar Cienfuegos-Jiménez; Salomón Álvarez-Cuevas; Antonio Ali Pérez-Maya; Gissela Borrego-Soto; Iván Alberto Marino-Martínez
Journal:  Int J Mol Epidemiol Genet       Date:  2021-06-15

10.  Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.

Authors:  Catherine O'Doherty; Alexander Favorov; Shirley Heggarty; Colin Graham; Olga Favorova; Michael Ochs; Stanley Hawkins; Michael Hutchinson; Killian O'Rourke; Koen Vandenbroeck
Journal:  Pharmacogenomics       Date:  2009-07       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.